‘We learn from each trial’: Alzheimer’s associations hopeful that Roche's gantenerumab data can inform future drug development
Roche announced yesterday that Phase 3 studies for its Alzheimer’s drug gantenerumab failed to meet the primary endpoint of slowing clinical decline. Although disappointed, Alzheimer’s associations are hopeful there is still a lot that can be learned...
